Molecule News and Research

RSS

Second molecular conductor discovered in some children with biliary atresia

Unexpected discovery of a new molecular signature for a destructive and often lethal pediatric liver disease may lead to a new therapeutic target for the hard-to-treat condition.

9 Nov 2011

University of Houston to enhance cancer research facilities

Thanks to almost $1 million in new funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Houston (UH) will soon be enhancing its cancer research facilities.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors

Celldex Therapeutics, Inc. today announced initiation of a Phase 1 study of its therapeutic human antibody candidate, CDX-1127, in patients with selected malignant solid tumors or hematologic cancers.

8 Nov 2011

Study: Genes that are active in brain are transcribed with special mechanism

Knowledge about the development of the nervous system is of the greatest importance for us to understand the function of the brain and brain disorders. Researchers at Uppsala University have examined the key step when genes are read and found that genes that are active in the brain are transcribed with a special mechanism.

8 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Researchers discover key mechanism responsible for degrading ubiquitinated protein aggregates

Researchers at the RIKEN Brain Science Institute (BSI) have discovered a key mechanism responsible for selectively degrading aggregates of ubiquitinated proteins from the cell.

7 Nov 2011

Scientists achieve major step toward goal of producing synthetic Taxol

Taxanes are a family of compounds that includes one of the most important cancer drugs ever discovered, Taxol, among other cancer treatments. But the difficulty producing these complex molecules in the lab has hampered or blocked exploration of the family for further drug leads. Now, a group of Scripps Research Institute scientists has successfully achieved a major step toward the goal of synthetically producing Taxol and other complex taxanes on a quest to harness chemical reactions that could enable research on previously unavailable potential drugs.

7 Nov 2011

Karolinska Institute researchers discover novel cancer drug target

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in the journal Nature Medicine. Researchers at the Karolinska Institute have discovered a novel cancer drug target.

7 Nov 2011

IFNa-kinoid shows promise against lupus

The first study to show results using active immunotherapy against the signaling protein interferon alpha in the treatment of lupus will be presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Chemical breakthrough could simplify drug development process

A new chemical process developed by a team of Harvard researchers greatly increases the utility of Positron Emission Tomography (PET) in creating real-time 3-D images of chemical process occurring inside the human body.

5 Nov 2011

Researchers identify surprising mechanism that facilitates protein interactions

Research led by St. Jude Children's Research Hospital scientists has identified an unexpected mechanism facilitating some protein interactions that are the workhorses of cells and, in the process, identified a potential new cancer drug development target.

5 Nov 2011

X-ray crystallography identifies structure of apoA-I molecule

Using a sophisticated technique of x-ray crystallography, researchers Xiaohu Mei, PhD, and David Atkinson, PhD, from Boston University School of Medicine (BUSM) have for the first time obtained an "image" of the structure and the precise arrangement of the atoms in a truncated form of the apolipoprotein A-I (apoA-I) molecule.

5 Nov 2011

Scientists identify mechanism by which GBM promotes neurodegeneration

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have discovered a mechanism by which glioblastoma multiforme (GBM), the most common form of brain cancer, promotes the loss of function or death of neurons, a process known as neurodegeneration.

4 Nov 2011

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

Using sub-nanometre cages to identify molecules

Reliable and accurate single-molecule medical diagnosis is a step closer to reality with the development a new technique by Cambridge University researchers which uses sub-nanometre “cages” to capture and identify molecules.

3 Nov 2011

ARIAD reports net income of $13.9 million for third quarter 2011

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter of 2011 and provided an update on its corporate developments.

3 Nov 2011

Eliminating senescent cells could prevent or delay onset of age-related disorders

Researchers at Mayo Clinic have shown that eliminating cells that accumulate with age could prevent or delay the onset of age-related disorders and disabilities. The study, performed in mouse models, provides the first evidence that these "deadbeat" cells could contribute to aging and suggests a way to help people stay healthier as they age.

3 Nov 2011

Nicotine might prime the brain to enhance behavioral effects of cocaine

A landmark study in mice identifies a biological mechanism that could help explain how tobacco products could act as gateway drugs, increasing a person's future likelihood of abusing cocaine and perhaps other drugs as well, according to the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The study is the first to show that nicotine might prime the brain to enhance the behavioral effects of cocaine.

3 Nov 2011